Acute treatment of migraine and the role of triptans
- 68 Downloads
The use of triptans has improved the ability to treat migraine successfully compared with older treatments. Speed of relief, consistency of effect, and good tolerability have been the hallmarks of these agents. All of the currently available triptans have comparable efficacy and tolerability. Variables between the agents may lead to one agent or dose form being preferred over another in various clinical scenarios. The triptans that are forthcoming may improve on these options through enhanced efficacy rates, tolerability, and headache recurrence rates. There exist increasing options for migraine treatment that may further improve the clinical effects of the older and newer triptans through early treatment of migraine at the stages of mild migraine pain, or even during the prodromal phase of the attack. Additionally, recent work suggests that mini-prophylaxis of migraine at the menses is a highly successful treatment option with the triptans. In this age of managed care, providing cost-effective treatment of headache will take on increasing importance. Techniques such as stratification of acute treatments may enhance cost-effective care, whereas ready availability of the triptans may lead to significant improvements in utilization of parameters such as office visits, emergency room treatment, and even hospitalization.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 3.DeVries P, Heiligers JP, Villalon CM, et al.: Blockade of porcine carotid vascular response to sumatriptan by GR127935, a selective 5HT1D receptor antagonist. Br J Pharmacol 1996, 118:85–92.Google Scholar
- 6.Maassen VanDenBrink A, Reekers M, Bax WA, et al.: Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998, 98:25–30. Although done in vitro, this study demonstrated the relatively small effects the triptans have on producing coronary artery constriction by themselves.Google Scholar
- 11.Freitag F, Diamond S, Diamond M, et al.: Subcutaneous sumatriptan in patients treated with monoamine oxidase inhibitors and other prophylactic agents. Headache Quarterly 1998, 9:165–171. This article demonstrated the low likelihood of significant clinical evidence of drug interaction, not just with the monoamine oxidase inhibitors, but also the selective serotonin re-uptake inhibitor antidepressants.Google Scholar
- 15.Elkind A, McDaris HL, Sati L, Keywood C: The cardiovascular safety of frovatriptan in patients at high risk of or with known coronary artery disease during a migraine attack. 9th Congress of the International Headache Society, Barcelona, Spain, June 22–26, 1999.Google Scholar
- 16.Cady R: Importance of early intervention in migraine. Advances in the understanding of migraine. A satellite education program of Headache Update 2000. Lake Buena Vista, FL, July 19, 2000.Google Scholar
- 20.Newman LC, Mannx LK, Silberstein SD, et al.: Naratriptan as prophylaxis for menstrually-associated migraine: a randomized, double blind, placebo-controlled study. Headache 2000, 40:422–423.Google Scholar
- 22.Lofland JH, Johnson NE, Batenhorst AS, Nash DB: Changes in resource use and outcomes for patients with migraine treated with sumatriptan: a managed care perspective. Arch Intern Med 1999, 26:857–863. Demonstrates the reduction in healthcare utilization because of migraine specific interventions.CrossRefGoogle Scholar
- 23.Goldfarb SD, Duncan BS, Dans PE, Sloan AS: HMO direct costs and health care resources use after implementation of a monthly limit on sumatriptan. Am J Health Syst Pharm 1999, 56:2206–2210. Shows the downside to managed-care regulation of amounts of triptans per prescription period on healthcare utilization.PubMedGoogle Scholar
- 24.Lipton RB, Stewart WF, Sawyer J: Stratified care is a more effective migraine treatment strategy than stepped care: results of a randomized clinical trial. Neurolgy 2000, 54(suppl 3):A14. Demonstrates the clinical and pharmacoeconomic advantages of stratified care versus stepped care for acute migraine in a clinical trial model.Google Scholar
- 25.Lipton RB: American Academy of Neurology, San Diego, CA, April 30-May 5, 2000.Google Scholar